Impact of the use of vasoactive drugs in cardiac death donors on the early postoperative renal function and related complications in renal transplant recipients

• Published in: Annals of translational medicine Vol. 8; no. 4; p. 116
• Main Authors: Zhang, Peng, Cao, Peihua, Fang, Jiali, Li, Guanghui, Zhang, Lei, Xu, Lu, Mo, Shijing, Lai, Xingqiang, Liu, Luhao, Xiong, Yunyi, Yin, Wei, Li, Li, Chen, Rongxin, Xu, Hailin, Zhang, Tao, Wan, Jiao, Guo, Yuhe, Ma, Junjie, Chen, Zheng
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01.02.2020
• Subjects: Original; complications; donation after cardiac death (DCD); vasoactive drugs; Kidney transplantation
• ISSN: 2305-5839; 2305-5839
• DOI: 10.21037/atm.2019.12.99

To explore the impact of the use of vasoactive drugs in donation after cardiac death (DCD) donors on graft function, with an attempt to guide the clinical practices of organ preservation and DCD kidney transplantation. The clinical data of 187 DCD donors and 304 recipients who were operated on in our center from February 2018 to May 2019 were retrospectively analyzed. Based on whether vasoactive drugs were used for maintaining blood pressure in DCD donors, the renal donors and recipients were divided into a high-dose group (norepinephrine ≥1.3 µg/kg/min or in combination with dopamine), a low-dose group (norepinephrine <1.3 µg/kg/min or in conjunction with dopamine), and a no-medication group (without the use of vasoactive drugs). The clinical features, post-transplant renal function, and complications were compared among these three groups. The early renal function 1 and 7 days after surgery was significantly superior in the high-dose group and no-medication group (P<0.05) but showed no significant difference between the low-dose group and the no-medication group (P>0.05). Blood urea nitrogen (BUN) on the 1st postoperative days was significantly higher in the high-dose group than in the low-dose group and the no-medication group (P<0.05). Renal function indicators, including serum creatinine (CRE), BUN, and blood uric acid (UA) on the 30th postoperative day, showed no significant difference among these three groups (P>0.05). The incidence of delayed graft function (DGF) after renal transplantation was significantly higher in the high-dose group than in the low-dose group and the no-medication group (P<0.05), whereas there was no significant difference between the groups in the incidences of graft rejection and infections (P>0.05). The use of vasoactive drugs in DCD donors can affect the early recovery of renal function in renal transplant recipients, particularly for those donors who are administered a high dose of vasoactive drugs. Therefore, donor maintenance should be performed cautiously with vasoactive drugs.